National Study of Moderate and Severe Von Willebrand Disease in the Netherlands (WiN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00510042|
Recruitment Status : Completed
First Posted : August 1, 2007
Last Update Posted : April 26, 2010
|Condition or disease|
|Von Willebrand Disease|
The incidence of von Willebrand disease in the Netherlands is unknown, but the occurrence of all types of von Willebrand disease together is estimated at 1:100-1:200 individuals. Most patients have mild von Willebrand disease, mostly type 1. For the more severe forms of von Willebrand disease the incidence in unclear, but the expectation is, that there are at least 500-1500 patients. In the Netherlands, an unique situation exists for the treatment of patients with hemophilia and related coagulation disorders. In 2000 a hemophilia management policy was set up by the Ministry of Health, which stated that the care for these patients should be concentrated in 13 Hemophilia Treatment Centers (HTC). The representatives of the attending centers, the hemophilia specialists, are organized in the NVHB, the Dutch society of Hemophilia treaters. In the hemophilia management policy is stated that all patients with a coagulation disorder dependent of replacement products must be treated in a HTC or under responsibility of a HTC. These patients are seen in a HTC at least once a year.
Because all moderate and severe von Willebrand patients in the Netherlands are known in HTC, it is possible to register and study this population. This is imperative to the research of von Willebrand disease. Because the moderate and severe forms of von Willebrand disease are rare, it is impossible for an individual center to perform research of moderate severe and severe von Willebrand disease. Therefore a national approach is necessary.
For optimal care of patients with the moderate and severe form of von Willebrand disease a better understanding of symptoms, diagnostics, treatment and complications of treatment is necessary. The present study aims to register and investigate all patients in the Netherlands with moderate and severe von Willebrand disease to gain understanding of the clinical presentation, the treatment and the complications of treatment in moderate and severe von Willebrand disease. Another goal is to investigate the influence of von Willebrand disease on quality of life.
To answer these questions a questionnaire is developed, which will be sent to the study population. In addition, blood will be drawn for von Willebrand factor measurement and plasma and DNA will be stored. The relationship between laboratory parameters, (including von Willebrand factor, FVIII and prothrombotic coagulation disorders) and the clinical phenotype in patients with moderate and severe von Willebrand disease will be studied. We will assess the effect of the laboratory parameters on both the severity of bleeding tendency, and the possible protecting effect on the risk of arterial thrombosis. In the future mutation analysis of the VWF gene will be performed in patients with moderate and severe von Willebrand disease in the Netherlands.
|Study Type :||Observational|
|Estimated Enrollment :||1100 participants|
|Official Title:||National Study of Moderate and Severe Von Willebrand Disease in the Netherlands|
|Study Start Date :||July 2007|
|Actual Study Completion Date :||September 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00510042
|Academic Medical Center Amsterdam|
|VU University Medical Center|
|Den Haag, Netherlands|
|Maxima Medical Center|
|University Medical Center Groningen|
|Leiden University Medical Center|
|Academic Hospital Maastricht|
|University Medical Center St. Radboud|
|Erasmus University Medical Center|
|Rotterdam, Netherlands, 3000 CA|
|University Medical Center Utrecht Van Creveldkliniek|
|Study Director:||Eva M de Wee, MD||Erasmus Medical Center|
|Principal Investigator:||Frank WG Leebeek, MD, PhD||Erasmus Medical Center|
|Study Chair:||Karin Fijn van Draat, MD, PhD||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|
|Study Chair:||Jeroen CJ Eikenboom, MD, PhD||Leiden University Medical Center|
|Study Chair:||Arja de Goede-Bolder, MD||Erasmus Medical Center|
|Study Chair:||Eveline P Mauser-Bunschoten, MD, PhD||Van Creveldkliniek, University Medical Center Utrecht|
|Study Chair:||Karina Meijer, MD, PhD||University Medical Center Goningen|
|Study Chair:||Britta Laros-van Gorkom, MD, PhD||University Medical Center St. Radboud Nijmegen|
|Study Chair:||Johanna G van der Bom, PhD||Leiden University Medical Center|
|Study Chair:||Manon A Degenaar-Dujardin, BA||Organization for Hemophilia Patients|